Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

ML, Telli; KC, Jensen; S, Vinayak; AW, Kurian; JA, Lipson; PJ, Flaherty; K, Timms; V, Abkevich; EA, Schackmann; IL, Wapnir; RW, Carlson; PJ, Chang; JA, Sparano; B, Head; LJ, Goldstein; B, Haley; SR, Dakhil; JE, Reid; AR, Hartman; J, Manola; JM, Ford

doi:10.1200/jco.2014.57.0085

Public

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

Shared by NobleBlocks on Apr 6, 2015 • 12:00 AM UTC

Authors:

Telli ML

Jensen KC

Vinayak S

Abstract

<h4>Purpose</h4>This study was designed to assess efficacy, safety, and predictors of response to iniparib in combination with gemcitabine and carboplatin in early-stage triple-negative and BRCA1/2 mutation-associated breast cancer.<h4>Patients and methods</h4>This single-arm phase II study enrolled...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!